Switching from Invega to Risperidone After Short-Term Exposure
Rationale for Direct Switch
- The American Academy of Child and Adolescent Psychiatry suggests that a 4-day exposure to Invega is insufficient for significant neuroadaptive changes to occur, making a gradual taper unnecessary 1
- The general principle of gradual tapering to avoid withdrawal symptoms or rebound worsening of symptoms applies primarily to patients on established antipsychotic treatment, not those with ultra-short exposures like 4 days 1
Practical Implementation
- In an inpatient setting, it is recommended to stop Invega immediately and start risperidone 1 mg BID on the same day, allowing for ideal monitoring conditions for the direct switch 1
- The inpatient setting provides ideal monitoring conditions for this direct switch, allowing rapid assessment of clinical response and side effects 1
Critical Monitoring Parameters
- Monitor for extrapyramidal symptoms (EPS) daily, as risperidone has higher D2 antagonism than paliperidone at equivalent doses 2
- Check orthostatic vital signs for the first 3-5 days, as risperidone can cause orthostatic hypotension during initial titration 2
- Assess psychotic symptom severity daily using standardized scales to ensure no symptom exacerbation occurs 2
- Watch for sedation, which may be more pronounced with risperidone compared to paliperidone 2